Loading clinical trials...

The Ischemia Modified Albumin In Diagnosing Ischemic New Events | Clinical Trials | Clareo Health

TERMINATED

The Ischemia Modified Albumin In Diagnosing Ischemic New Events

The Ischemia Modified Albumin In Diagnosing Ischemic New Events (IMAGINE Study).

NCT00355992•Inverness Medical Innovations

Summary

The purpose of the study is to evaluate the utility of Ischemia Modified Albumin (IMA) for risk stratification in patients presenting with chest discomfort and possible ischemic heart disease, and to evaluate the diagnostic and prognostic implication for IMA for major adverse cardiac events.

Eligibility

Age

21 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Age \>=21 years
•Presentation within two hours of relief of most recent episode of chest pain or presence of on-going symptoms suggestive of coronary ischemia, which should be at least 10 minutes in duration.
•Patients being evaluated for suspected ischemic signs and or symptoms (chest pain) at the time of presentation according to routine standard of care institutional chest pain protocol/pathway.

Exclusion Criteria

•Administration of thrombolytic medication prior to first (presentation) blood draw
•Acute coronary syndrome (ACS) secondary to supply/demand inequity (i.e. known anemia, tachycardia, - defined as HR greater than 150 bpm, known sepsis, hypotension, defined as blood pressure \< 90 mmHg).
•Established diagnosis of liver cirrhosis
•Other acute ischemic sources (ongoing severe claudication, mesenteric ischemia, acute TIA/CVA)
•Renal failure requiring dialysis
•Greater than 2 hours from relief of the most recent episode of chest pain or signs and symptoms suggestive of coronary ischemia.
•Chest pain following traumatic injury to the chest
•Evidence for sever systemic infection, manifesting as fever (temperature \>100 degrees) and systolic blood pressure \<100 mmHg
•Patients unwilling or unable to provide written consent, without available next of kin
•Cocaine-related chest pain
+5 more criteria

Locations (5)

Massachusetts General Hospital

Boston, Massachusetts, United States

Dartmouth Medical Center

Lebanon, New Hampshire, United States

Cleveland Clinic

Cleveland, Ohio, United States

Vanderbilt University

Nashville, Tennessee, United States

Hamilton General Hospital

Hamilton, Ontario, Canada

Key Dates

Start Date

September 1, 2006

Completion Date

December 1, 2007

Last Updated

May 12, 2009

Enrollment

1,250

ESTIMATED participants

Conditions

Heart Disease, IschemicIschemia, MyocardialIschemic Heart DiseaseUnstable Angina

Essential Pro Study ( rEPIC04E-HK )

NCT06631157

Coronary Artery DiseaseIschemic Heart Disease

View study

RECRUITING

Sequent Extended Study

NCT05788432

Coronary Artery DiseaseIschemic Heart Disease

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 12, 2009Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

The Ischemia Modified Albumin In Diagnosing Ischemic New Events

Inclusion Criteria

Exclusion Criteria

Essential Pro Study ( rEPIC04E-HK )

Sequent Extended Study

Treatment of Functionally Non-significant Vulnerable Plaques in Patients With Multivessel ST-elevation Myocardial Infarction The VULNERABLE Trial

A Clinical Evaluation of AMJ-401

CMR Prognostic Markers in Ischemic Heart Disease

Development of CIRC Technologies